HyBryte™ Clinical Summary Published in “Expert Opinion on Investigational Drugs”
“We are pleased to have Dr. Poligone and his team review the compelling data generated from the HyBryte™ clinical program, enabling the medical community to evaluate its safety, efficacy and utility in early-stage CTCL,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “We look forward to continuing our work with Dr. Poligone and all our principal investigators as we move towards completing patient enrollment in the FLASH2 Phase 3 study later this year, with an interim analysis of this study expected in 2Q 2026.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data